Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer.

J Clin Med · 2026 · PMC13073025 · PMID 41977106

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.1900

boldest claim

The sentences

of borderline significancep = 0.062so close (0.05 < p ≤ 0.1)

The use of bevacizumab in second or later lines remained of borderline significance in the multivariable model (HR 0.69; p = 0.062) ( Table 5 ). 4.

also in 1,491 other papers

showed a trendp = 0.066so close (0.05 < p ≤ 0.1)

Lung metastasis showed borderline significance (HR 1.34; p = 0.071), and the use of bevacizumab in second or later lines showed a trend toward reduced mortality (HR 0.70; p = 0.066).

also in 31,039 other papers

borderline significancep = 0.079so close (0.05 < p ≤ 0.1)

Peritoneal metastasis ( p = 0.693), de novo metastatic disease ( p = 0.264), and MSI-H status ( p = 0.074) lost statistical significance, while liver metastasis showed borderline significance (HR 1.62; p = 0.079) ( Table 3 ).

also in 3,927 other papers

did not reach statistical significancep = 0.190not close (p > 0.1)

In the mucinous subgroup, irinotecan-based regimens were associated with numerically longer PFS; however, this difference did not reach statistical significance (24.1 vs. 16.2 months; p = 0.190).

also in 61,332 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.